Opinion 10 Nov 2021 Automation Can Solve Diversity Issues in Clinical Trial Recruitment How can we make clinical trial recruitment more reflective of the real world? Technology is coming to the rescue. The quest for diversity in clinical trials goes to the heart of patient care. Why are some demographic groups over-represented in studies when others are more difficult to recruit? Studies that fail to reflect patient demographics […] November 10, 2021 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2021 Valneva’s Inactivated Covid-19 Vaccine Aces Phase III Trial Last week, the French vaccine maker Valneva announced promising phase III trial results of its inactivated Covid-19 vaccine: a well-established technology that could confer broader immunity to the virus than shots currently on the market. Valneva’s vaccine candidate consists of a killed or ‘inactivated’ version of SARS-CoV-2, the virus responsible for Covid-19. The vaccine was […] October 26, 2021 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2021 As J&J Vaccine Fails Phase II, the Quest for an HIV Vaccine Continues Johnson & Johnson became the latest company to have a failed vaccine trial against HIV last week. While it was a great disappointment to many, efforts continue in this space, helped by recent Covid-19 vaccine advances. HIV has been around for decades. While antiretroviral treatments have improved enormously, turning what was once a death sentence […] September 8, 2021 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 2 Sep 2021 AC Immune’s Mixed Phase II Results Buoy Alzheimer’s Research An Alzheimer’s disease drug developed by AC Immune and Genentech has drawn conflicting phase II results this week, raising tentative hopes for the field of treatments targeting the protein tau. For decades, the major culprit responsible for Alzheimer’s disease was suggested to be the buildup of a protein called amyloid-beta in the brain. Blocking this […] September 2, 2021 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 29 Apr 2021 BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel immune checkpoint target in nearly a decade. This could herald the next generation of checkpoint inhibitors against cancer. Last month, the antibody drug relatlimab, developed by Bristol Myers Squibb, increased the progression-free survival of melanoma patients in phase III. These […] April 29, 2021 - 5 minutesmins - By Mark Zipkin Share WhatsApp Twitter Linkedin Email
News and Trends 27 Apr 2021 EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations centered mostly on improving existing approaches. Which areas of multiple sclerosis treatment need more options? At the end of March, the EMA made key decisions on three treatments for multiple sclerosis (MS), a chronic neurodegenerative disease affecting 2.5 million people […] April 27, 2021 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Sponsored by PCMG 8 Jun 2020 Why Biotechs Should Invest in Good Outsourcing Management of CROs The relationship between biotechs and their CRO partners has been long in the making. These days, a collaboration with CROs is seen as a standard in the drug development industry. However, the management of drug development partners and providers can be highly challenging for biotechs. This is where outsourcing expertise can make the difference between […] June 8, 2020 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Expert Advice 12 Mar 2020 Five Challenges For Life Science Marketers in 2020 Developing a new drug has an estimated cost of €583M to €2.4B. Much of this spending goes towards companies, such as vendors, CROs, and CDMOs, who generate value by commercializing and industrializing innovations to improve the ways researchers study organisms and viruses in the early stages of drug development. For those of us in sales […] March 12, 2020 - 14 minutesmins - By Mark Livingstone Share WhatsApp Twitter Linkedin Email